SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: A packaged Set of semaglutide injection
Drug Development
Patients Taking Semaglutide See Benefit After Total Hip Replacement
Studies presented Monday at the American Academy of Orthopaedic Surgeons annual meeting show semaglutide has positive impact on outcomes for total hip arthroplasty patients.
February 13, 2024
 · 
2 min read
 · 
Tyler Patchen
Biogen’s headquarters in Massachusetts
Business
Biogen Misses Q4 Revenue Estimates on Aduhelm Costs, Lower MS Drug Sales
In the fourth quarter of 2023, Biogen’s revenue from multiple sclerosis drugs fell 8% due to generics competition and the company paid $60 million in close out costs related to Alzheimer’s treatment Aduhelm.
February 13, 2024
 · 
2 min read
 · 
Tyler Patchen
Deals
With Catalent’s Latest Quarterly Numbers Down, Experts Reaffirm Novo’s Buy 
Analysts say Novo Holdings made the right decision last week in scooping up the CDMO to increase manufacturing capacity for Novo Nordisk’s diabetes and weight-loss drugs.
February 13, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: Gilead's headquarters in Silicon Valley/
Deals
Gilead to Buy CymaBay, Lead Liver Disease Asset Seladelpar for $4.3B
Gilead Sciences announced Monday it will purchase CymaBay Therapeutics and its investigational treatment seladelpar for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.
February 12, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: 3D illustration of a damaged liver/iStoc
Drug Development
Madrigal Touts Positive Phase III NASH Data for Resmetirom Ahead of PDUFA Date
Madrigal Pharmaceuticals announced late-stage results published Thursday in The New England Journal of Medicine for resmetirom as it awaits a March 14 PDUFA date.
February 9, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Gilead's headquarters in Silicon Valley/
Drug Development
Gilead Axes Blood Cancer Treatment After Risk of Death Identified by FDA
Gilead Sciences is ending the development of magrolimab for the treatment of blood cancer following the FDA’s placement of a clinical hold on all its programs related to the drug.
February 8, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Inside of Kyowa Kirin headquarters/compa
Business
Kyowa Kirin Pays $100M Upfront to BridgeBio for Skeletal Dysplasias Drug in Japan
Kyowa Kirin’s dealmaking continued on Wednesday when BridgeBio Pharma granted the Japanese company an exclusive license to develop and commercialize infigratinib.
February 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Sign outside BioNTech's building in Germany
Business
BioNTech Inks $250M Deal with Autolus to Advance CAR-T Assets
BioNTech will pay $50 million in cash and purchase $200 million of Autolus Therapeutics’ shares to progress the companies’ respective CAR-T candidates to commercialization.
February 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Two business professionals in suits shaking hands
Business
Jazz Inks Potential $880M Deal with Redx to Buy KRAS Inhibitors
Jazz Pharmaceuticals is acquiring Redx Pharma’s KRAS inhibitor program including preclinical-stage drug candidates, with the companies working to advance assets through IND-enabling studies.
February 7, 2024
 · 
2 min read
 · 
Tyler Patchen
Facade of Novo Nordisk's office in Fremont, California
Deals
Novo’s Catalent Acquisition Surprises Some Analysts, Raises Questions About Existing Contracts
While analysts are bullish on Novo Holdings’ $16.5 billion acquisition of Catalent, they say it raises questions for companies that have contracted the CDMO for manufacturing.
February 7, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: Pill Collage/Taylor Tieden for BioSpace
Policy
Drug Shortages Aren’t Over. And There’s Little Progress Toward Ending Them
With manufacturing issues persisting, last year’s shortages of medicines, including chemotherapies, weight-loss drugs and antibiotics, will continue into 2024.
February 6, 2024
 · 
6 min read
 · 
Tyler Patchen
Pictured: Johnson & Johnson Sign/iStock, JHVEPhoto
Drug Development
J&J Touts Positive Phase III Results for Antibody in Autoimmune Disorders
The monoclonal antibody Nipocalimab, which J&J acquired from Momenta Therapeutics, met its primary endpoints in mid-stage and late-stage trials in myasthenia gravis and Sjögren’s disease.
February 6, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Healthcare worker administering a vaccin
Policy
Valneva Sells Chikungunya Vaccine Priority Review Voucher for $103M
The French vaccine maker on Monday said it sold a priority review voucher, which was awarded by the FDA in November 2023 alongside an approval for its chikungunya vaccine, to an undisclosed buyer.
February 6, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Eli Lilly World Headquarters/iStock, jet
Business
Lilly Beats Q4 Revenue Estimate Fueled by Strong Zepbound, Mounjaro Sales
Eli Lilly on Tuesday reported more than $9.3 billion in revenue in the fourth quarter of 2023, beating Wall Street expectations, thanks to demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro.
February 6, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: Nasdaq signage and building in New York City
Deals
Genome Editing Biotech Metagenomi Targets IPO to Raise $86.9M
Metagenomi could potentially raise over $100 million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $16 per share.
February 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More